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Accepted 4 February 2013AbstractObjectives: To illustrate that matching on provider may exacerbate, not remove, bias.
Study Design and Setting: The degree of confounding bias depends in part on the proportions of treatment variation that can be as-
cribed to confounders and to instruments, respectively. This commentary raises the specific example of bias by matching on hospital in-
duced in a study of coronary artery bypass graft surgery patients and illustrates the effect of matching on provider in a constructed example.
Results: Matching on provider removes a ‘‘benign’’ source of treatment variability, leaving unmeasured confounders as potentially the
most important determinants of treatment.
Conclusions: Researchers need to articulate the presumed source of pseudorandom variation in observational studies and need to take
care not to reduce their effect through unnecessary control.  2013 Published by Elsevier Inc.
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Epidemiologists working with clinical data typically
worry over potential confounding factors, the characteris-
tics associated with treatment choice that also predict the
outcome. The characteristics that do not affect disease
(other than through their influence on treatment) may not
receive separate attention, which could leave us open to
bad design choices such as inclusion in matching. Brook-
hart et al. [1] have termed the error that results from control
for instruments (correlates treatment that do not predict out-
come) ‘‘Z-bias.’’ Pearl [2,3] introduced the term ‘‘bias am-
plification’’ to describe the same magnification of error.
The purpose of this commentary was to illustrate the impli-
cations of Z-bias for matching on provider.
Reasoning by false analogy to good trial design could
lead epidemiologic researchers to match on provider in
noninterventional studies. Blocking by research site is the
standard in randomized clinical trials (RCTs) because fea-
tures of the clinic or the patient may vary from site to site.
‘‘Ensure that the assigned treatments are balanced within
site,’’ goes the reasoning, ‘‘in order to avoid subtle correla-
tions between treatment and unmeasured determinants of
risk.’’ However, this advice is not equally applicable to
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correlation between treatment and outcome predictors re-
lated to site and in so doing also maximizes treatment var-
iation within site. The epidemiologist could perform
matching of subjects within site to eliminate correlation be-
tween treatment assignment and predictors related to site
but in so doing may dramatically reduce treatment variation
overall.
Practitioners of observational studies appeal to ‘‘pseudo-
random’’ determinants of treatment. Pseudorandomization
comes from aspects of clinical practice that patients inad-
vertently choose when they decide which doctor to see or
which clinic to attend. Pseudorandom treatment assignment
is deterministic and depends on factors that are uncorre-
lated with outcome, such as doctors’ acquired preference,
formulary, guidelines, and cost. When pseudorandomiza-
tion holds, there is no correlation between nontreatment
predictors of outcome and treatment itself, so we can pro-
ceed analytically as if the treatment had been given accord-
ing to a truly randomized plan.
Doctors do not flip coins. If a physician chooses differ-
ent treatments for two patients who are identical according
to our data, then almost certainly the data are incomplete.
The physician will have acted for a reason, perhaps a per-
ception of frailty or knowledge of family history or the
inefficacy of previous treatments. The same doctor on sub-
sequent days with patients similar in every aspect of prog-
nosis will nearly always choose the same treatment.
Consistency of behavior is a commonly noted virtue ine.
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 Determinants of treatment in observational studies
are either instruments or confounders.
 Control for instruments amplifies the bias induced
by confounders.
 Provider is a strong instrument for treatment
choice.
 Matching on provider may therefore increase bias.
practitioners that is in fact the basis for using the therapy
given to a patient seen earlier as an instrument for therapy
given to a patient under study [4].
The researcher who eliminates some unmeasured con-
founders through the use of an instrumental variable such
as physician identitymay also removemajor sources of pseu-
dorandom variation through the same maneuver [5]. If
unmeasured confounders remain after matching on an instru-
ment, they may be the only remaining determinants of varia-
tion in treatment within the matched group. The result is that
with matching, factors that otherwise may have been only
a small part of overall treatment heterogeneity and quantita-
tively small contributors to bias become unique sources of
treatment variation and therefore potent confounders.
Decades have passed since McKinlay [6] noted, ‘‘Pair-
matching is undoubtedly one of the most popular tech-
niques for controlling variation in both medical and other
investigations involving human populations.’’ Happily, pair
matching by provider does not appear to be common in cur-
rent comparative effectiveness research, but it remains
a good illustrative example for exploring the dangers of co-
hort matching.2. Example
Table 1 presents an analysis of the comparative efficacy
of two agents in preventing death in patients undergoing
coronary artery bypass graft surgery in the United States
[7]. Both aprotinin and aminocaproic acid increase blood
coagulation and reduce the need for blood transfusions.
The first column of results shows the relative mortality of
recipients of various doses of aprotinin compared with that
of recipients of aminocaproic acid. The estimates were ob-
tained by logistic regression that included a wide range ofTable 1. The effect of matching for hospital on the estimated relative
aminocaproic acid during coronary artery bypass graft surgery [2]
Aprotinin dose
Standard logistic regression with
covariate control
Very low 1.32 (1.08e1.60)
Low 1.36 (1.18e1.56)
High 1.75 (1.56e1.97)patient and hospital characteristics. This was the per-
protocol analysis.
That the covariates were confounders had been indicated
by a drop of about 30% going from crude to adjusted rela-
tive risk estimates (See the original publication for details.).
This was consistent with reports from thoracic surgeons
that aprotinin would be used more commonly for sicker
patients and in operations for recurrent coronary artery
obstruction.
A reviewer proposed that the effect in the first column of
results might be attributable to confounding by unmeasured
factors and suggested that there should be an analysis
matched on hospital. The results are in the second column,
in which the effect estimates from the matched analysis
were about 40% higher than those from the unmatched
analysis.
An a priori expectation that confounding would exagger-
ate the possible higher mortality in the aprotinin group had
been borne out in the original adjusted analysis, but far
from further lowering relative risk estimate, matching for
hospital pushed the relative risk estimates substantially
higher.3. Numerical illustration
To show the effect of removing benign variation from
an analysis, we conducted numerical illustrations of the
diseaseeexposure relations for data sets constructed using
the directed acyclic graph in Fig. 1. Note in the figure that
variation in the provider is a source of variation in the treat-
ment choice but is otherwise unrelated to any node in the
graph. Along with the various unmeasured sources of vari-
ation in confounder, treatment, and disease, provider is an
exogenous variable. To illustrate the effect of controlling
for provider (P in the figures) or not, each of the exogenous
unmeasured factors and provider was represented as a ran-
dom normal variate on an Excel spreadsheet. In 100 repli-
cations representing cohort studies with varying intensities
of treatment, the value of each exogenous factor was drawn
at random from a normal distribution. The values of factors
at the endogenous nodes were calculated as the sums of the
contributing variates. The effect of treatment was modeled
as reducing the intensity of disease (D in the figures) by
giving it a negative coefficient in the diseaseeintensity
sum. The confounder was taken similarly to increase the
values for treatment (T in the figures) and of disease. The
means and standard deviations of the different factors were
chosen exclusively with an eye to making informativemortality of patients given aprotinin compared with patients given
Conditional logistic regression with
covariate control and matching by hospital
1.82 (1.42e2.34)
1.78 (1.47e2.16)
2.47 (2.10e2.90)
Fig. 1. Directed acyclic graph underlying the numerical illustrations.
C, confounding characteristic; T, treatment; D, disease; P, provider;
UC, UT, and UD, unmeasured determinants of confounder, treatment,
and disease, respectively.
Fig. 2. The relation between treatment and disease with no control for
provider effects. The preventative effect of treatment on disease is
evident.
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ables were also adjusted for the purposes of display. None
of these are meant to represent any specific study. All the
values at the nodes of Fig. 1 were taken as continuous vari-
ables, so the points should be thought of as large group
averages of each of the variables. The points displayed in
Figures 2 and 3 could be thought of as the results of 100
different cohorts, each with an average level of treatment
and an average level of disease, as illustrated.
Fig. 2 shows the relation between disease and exposure
over 100 replications when the provider was allowed a de-
gree of variation (a standard deviation) four times larger
than that associated with the exogenous determinants of
treatment (UT). The standard deviation of the exogenous
determinants (UC) of the confounder (C in the figures) is
2.5 that of UT. C, UT, and P are similarly influential on
T. The resulting negative relation between treatment and
disease is readily apparent.
Fig. 3 shows what happens with complete control
for provider, modeled by reducing the variability in pro-
vider to zero. With the now feeble variation in treatment
that is ascribable to exogenous sources, variation in the
confounder is the dominant source of treatment variation,
and as a consequence, the confounderedisease association
drives the appearance of the treatmentedisease relation.Fig. 3. The relation between treatment and disease with complete
control for provider effects. The preventative effect of treatment on
disease is no longer evident; the apparent positive relation between
treatment and disease, induced by the confounder, dominates. None
of the coefficients of the relations differ between Figures. 2 and 3.
Only the treatment variability ascribed to provider changes.4. Conclusion
When we restrict the sources of pseudorandom variation
in treatment, we increase bias from those unmeasuredconfounders that have not been blocked in the restriction.
It may be a healthy discipline for us to articulate the pre-
sumed sources of the ‘‘good variation’’ in observational re-
search studies. We have become practiced in speculating
about and even quantifying the causes of ‘‘bad variation,’’
in which an unmeasured correlate of treatment is a determi-
nant of outcome. If a researcher cannot clearly, specifically,
and plausibly point to the sources of good variation in
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inference that invokes pseudorandom variation.
The absence of plausible mechanisms for pseudorandom
variation after tight matching in medical studies may ac-
count for the rarity of provider matching. Imagine an inves-
tigator asserting, ‘‘Among patients with identical covariate
patterns and the same prescriber, we believe that essentially
all the variation in treatment selection arises from factors
such as [sales visits? study? in-service education?] that
have no relation to prognosis.’’ Most often the claim would
be speculative and unwarranted. Even to conceive of,
let alone document, the nonpatient determinants that might
account for intraprovider treatment variation is a challenge.
But a reader should expect nothing less than a similar state-
ment whenever potent determinants of exposure have been
accounted for through matching of any kind.
Reduction in variability in treatment is not by itself either
desirable or to be avoided. However, the ratio of ‘‘good’’ to
‘‘bad’’ variation will dramatically affect the quantitative im-
pact of unmeasured confounding. Constructing realistic sce-
narios for the processes that give rise to the data is a strong
way to gain insight into the sociology and medicine that set
the stage for research. Being conscious of the reasons to be-
lieve that good variation dominates bad may prevent us from
introducing unnecessary restriction into study designs. Or it
may lead us to back off from strategies such as providermatching, where too much control can be a greater evil than
not enough.References
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